Back to top

Analyst Blog

Zacks Equity Research

Allergan's Botox Finding Other Uses

AGN

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Allergan, Inc. (AGN - Analyst Report) announced positive data from two phase III trials of Botox (onabotulinumtoxinA). The trials evaluated the drug in patients with idiopathic overactive bladder (OAB), who were suffering from urinary incontinence and responded inadequately or were intolerant to anticholinergic treatment (current standard of care).

The trials witnessed significant reduction in the episodes of urinary incontinence when Botox was used as compared to placebo. The company plans to present the full results from the trials at an upcoming scientific meeting.

Armed with the encouraging results, the company has filed for regulatory approval in both US and Europe for the use of Botox in adult patients who suffer from OAB with symptoms of urinary incontinence, urgency and frequency, and do not show adequate response to anticholinergic treatment.

Last year in August, Botox received US Food and Drug Administration (FDA) approval for the treatment of neurogenic OAB. We note that neurogenic OAB was the seventh indication for which Botox has received approval in the US. In October 2010, the FDA approved Botox for the treatment of chronic migraine headache in adults.

The other uses of the drug comprise treatment of increased muscle stiffness in elbow, wrist, and finger muscles in adults with upper limb spasticity; treatment of abnormal head position and neck pain that happens with cervical dystonia in patients aged 16 years and above; and treatment of certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in patients aged 12 years and above.

Botox is also used to treat the symptoms of severe underarm sweating in adults. Additionally, Botox Cosmetic is used to temporarily improve the appearance of moderate to severe facial wrinkles in adults.

Our Take

We note that Botox, which faces fierce competition in the US from Medicis Pharmaceutical Corp.’s Dysport, posted sales of $1.6 billion in 2011 (up 12.4% from the year-ago period). Botox is the key product of Allergan, representing almost 30% of net product sales. Cosmetic and therapeutic indications contribute equally to total Botox sales.

Allergan expects Botox sales in the range of $1.7 billion – $1.8 billion in 2012. We believe that the 2012 Botox guidance is achievable considering the 78% share Botox enjoys of the $2.1 billion global neuromodulators market, which is growing at a rate of 16%. We expect that positive results in the idiopathic OAB indication can translate into a regulatory approval thus contributing to an upside in sales.

We currently have a Neutral recommendation on Allergan, which is supported by a Zacks #3 Rank (short-term Hold rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%